Literature DB >> 16606866

APOE alleles are not associated with calcific aortic stenosis.

J R Ortlepp1, M Pillich, V Mevissen, C Krantz, M Kimmel, R Autschbach, G Langebartels, J Erdmann, R Hoffmann, K Zerres.   

Abstract

OBJECTIVES: To analyse the association of APOE alleles with aortic stenosis (AS) in a large study population.
METHODS: Patients with AS (n = 538) and a control group of the same age without heart disease (n = 536) were recruited. Left heart catheterisation was performed and mean gradient, aortic valve area, presence of stenotic coronary artery disease (CAD) and cardiovascular risk factors (hypercholesterolaemia, hypertension, smoking, diabetes mellitus and family history of CAD) were assessed. The frequency of the APOE major alleles e2, e3 and e4 was assessed by genotyping the polymorphisms APOE334 and APOE472 with a 5' exonuclease assay (TaqMan).
RESULTS: Mean gradient across the aortic valve in cases was 50 (SD 20) mm Hg corresponding to a mean aortic valve area of 0.84 (SD 0.34) cm(2). 270 patients with AS had stenotic CAD. Among patients with AS, the prevalence of hypercholesterolaemia (64% v 40%, p < 0.001), smoking (43% v 27%, p < 0.001), diabetes (27% v 17%, p < 0.01), family history of CAD (30% v 21%, p </= 0.05), and male sex (65% v 44%, p < 0.001) was higher in those with than in those without CAD. The frequency of the major alleles was not different between cases and controls (APOE e2: 104 (19.3%) v 94 (17.5%); APOE e3: 319 (59.3%) v 332 (61.9%); APOE e4: 115 (21.3%) v 110 (20.5%); all p > 0.10).
CONCLUSION: APOE e4 is not associated with AS, reflecting the different genetic backgrounds of CAD and AS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16606866      PMCID: PMC1861026          DOI: 10.1136/hrt.2005.075317

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  35 in total

1.  The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis.

Authors:  J R Ortlepp; R Hoffmann; F Ohme; J Lauscher; F Bleckmann; P Hanrath
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

Review 2.  Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies.

Authors:  Rosario V Freeman; Catherine M Otto
Journal:  Circulation       Date:  2005-06-21       Impact factor: 29.690

3.  Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study.

Authors:  B F Stewart; D Siscovick; B K Lind; J M Gardin; J S Gottdiener; V E Smith; D W Kitzman; C M Otto
Journal:  J Am Coll Cardiol       Date:  1997-03-01       Impact factor: 24.094

4.  The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study.

Authors:  L U Gerdes; C Gerdes; K Kervinen; M Savolainen; I C Klausen; P S Hansen; Y A Kesäniemi; O Faergeman
Journal:  Circulation       Date:  2000-03-28       Impact factor: 29.690

5.  Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Authors:  G M Novaro; I Y Tiong; G L Pearce; M S Lauer; D L Sprecher; B P Griffin
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

6.  Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study.

Authors:  S E Humphries; P J Talmud; E Hawe; M Bolla; I N Day; G J Miller
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

7.  Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study.

Authors:  C Lahoz; E J Schaefer; L A Cupples; P W Wilson; D Levy; D Osgood; S Parpos; J Pedro-Botet; J A Daly; J M Ordovas
Journal:  Atherosclerosis       Date:  2001-02-15       Impact factor: 5.162

8.  Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves.

Authors:  M Olsson; J Thyberg; J Nilsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-05       Impact factor: 8.311

9.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.

Authors:  S Joanna Cowell; David E Newby; Robin J Prescott; Peter Bloomfield; John Reid; David B Northridge; Nicholas A Boon
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

10.  [Epidemiological investigations of the chances of preventing, recognizing early and optimally treating chronic diseases in an elderly population (ESTHER study)].

Authors:  M Löw; C Stegmaier; H Ziegler; D Rothenbacher; H Brenner
Journal:  Dtsch Med Wochenschr       Date:  2004-12-03       Impact factor: 0.628

View more
  1 in total

Review 1.  Genetic predisposition to calcific aortic stenosis and mitral annular calcification.

Authors:  Anton G Kutikhin; Arseniy E Yuzhalin; Elena B Brusina; Anastasia V Ponasenko; Alexey S Golovkin; Olga L Barbarash
Journal:  Mol Biol Rep       Date:  2014-06-06       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.